Shots:

• Immunology focuses on analyzing all aspects of the immune system in both healthy and diseased states, from its structure & function to its disorders, blood banking, immunization & organ transplant
• Along with the enhanced utilization of immunotherapies for immunological & autoimmune diseases, monoclonal antibodies have also showcased a great potential to be used as a treatment option. As in 2021, Abbvie again secured the top position with total revenue of $25.24B, followed by J&J, Roche, and Amgen
• Our team at PharmaShots has compiled a list of the top 20 immunology companies based on their 2021 immunology revenue

Immunology Segment Revenue: $0.014B

Founded Year: 1979

Market Cap: N/A

Total Employees: ~200

Headquarters: New Jersey, United States

Stock Exchange: NASDAQ

Antares Pharma is a pharmaceutical company that develops pharmaceutical products and technologies including needle-free and mini-needle injector systems and transdermal gel technologies. Otrexup was the key player in its immunology segment generating the total revenue. Antares Pharma’s 2021’s revenue declined by 6.67% vs. 2020. On Dec’21 Antares Pharma’s Otrexup was acquired by Assertio Holdings to advance its product pipeline whereas in May’22 Antares Pharma was acquired by Halozyme Therapeutics.

Immunology Segment Revenue: $0.12B

Founded Year: 1993

Market Cap: $1.61B

Total Employees: ~5,290

Headquarters: Shenyang, China

Stock Exchange: HKG

3S Bio is a Chinese Biotechnology company that develops and commercializes biopharmaceutical products along with recombinant or genetically engineered, protein-based products in the areas of oncology, nephrology, dermatology, and auto-immune diseases. 3S bio immunology segment is boosted by the sales of its lead product, Yisaipu. 3S Bio’s 2021 revenue increased by 33.30% vs. 2020. On Dec’21, 3SBio expanded its partnership with Numab for the development and commercialization of NM28.

Immunology Segment Revenue: $0.81B

Founded Year: 2007

Market Cap: $0.008B

Total Employees: ~6,700

Headquarters: Osaka, Japan

Stock Exchange: TYO

Mitsubishi Tanabe Pharma is a pharmaceutical company dedicated towards providing therapeutic options across areas including Diabetes, Kidney Diseases, Autoimmune Diseases & Vaccines. The products contributing to the company’s immunology segment are Stelera, Simponi & Imusera. Mitsubishi’s 2021 revenue was boosted by 14.08% vs. 2020. On Jan’21, Mitsubishi joined forces with Pharma Foods International to develop a therapeutic antibody for autoimmune diseases.

Immunology Segment Revenue: $1.12B

Founded Year: 1891

Market Cap: $226.38B

Total Employees: ~68,000

Headquarters: New Jersey, United States

Stock Exchange: NYSE

Merck & Co. is a global health care company that delivers health solutions through its prescription medicines, vaccines, biological therapies & animal health products. The company’s immunology segment includes Simponi & Remicade. Merck’s 2021 revenue was reduced by 3.45% vs. 2020. On Nov’21, Merck and Synthekine partnered to discover novel cytokine therapeutics utilizing Synthekine’s surrogate cytokine agonist platform.

Immunology Segment Revenue: $1.19B

Founded Year: 2000

Market Cap: $79.64B

Total Employees: ~91,960

Headquarters: Surrey, United Kingdom

Stock Exchange: LON

GSK is a global healthcare multinational company involved in the development, manufacture, and marketing of pharmaceutical products, vaccines, OTC medicines, and health-related consumer products. The immunology segment was one of the main drivers of its 2021 revenue. GSK’s 2021 revenue was boosted by 13.33% vs. 2020. On Jun’21 GSK collaborated with Progentec to analyse proteomics & digital health tools for Lupus.

Immunology Segment Revenue: $1.53B

Founded Year: 1923

Market Cap: $0.02B

Total Employees: ~14,520

Headquarters: Tokyo, Japan

Stock Exchange: TYO

Astellas is a Japanese pharmaceutical company that focuses on all therapeutic areas including Cardiology, Hematology, Immunology, Infectious Diseases, Oncology & Urology. The company’s net immunology revenue was generated through its product Prograf. Astellas’ 2021 revenue decreased by 7.27% vs. 2020. On Jul’21, the US FDA approved the sNDA for Astellas’ Prograf to prevent organ rejection in adult and pediatric lung transplant recipients.

Immunology Segment Revenue: $2.06B

Founded Year: 1978

Market Cap: $31.87B

Total Employees: ~9,610

Headquarters: Massachusetts, United States

Stock Exchange: NASDAQ

Biogen is a global biopharmaceutical company that provides therapies for autoimmune, neurological & neurodegenerative diseases. The company’s immunotherapy includes TYSABRI as a treatment option for autoimmune diseases. Biogen’s 2021 revenue showcased an increment of 6.18% vs. 2020. On Jul’21, Biogen settled for a license & collaboration agreement with Innocare for Orelabrutinib.

Immunology Segment Revenue: $2.07B

Founded Year: 2008

Market Cap: $15.46B

Total Employees: ~1,890

Headquarters: Dublin, Ireland

Stock Exchange: NASDAQ

Horizon Therapeutics is a biopharmaceutical company that targets the discovery, development & commercialization of medicines for autoimmune & severe inflammatory diseases. The net sale of the company’s immunology segment was based on the sales of Tepezza, Rayos, Duexis, Vimovo & Pennsaid. Horizon’s 2021 revenue was inclined by 68.29% vs. 2020. On Dec’21, Horizon Therapeutics collaborated with Alpine Immune Sciences to develop protein-based therapies for autoimmune & inflammatory diseases

Immunology Segment Revenue: $2.09B

Founded Year: 1928

Market Cap: $3.44B

Total Employees: ~8,560

Headquarters: Brussels, Belgium

Stock Exchange: EBR

UCB is a biopharmaceutical company dedicated to the development of products based on therapeutic areas including CNS &Immunology. Under the company’s immunotherapies Cimzia ($2.0B) had more contribution to the total revenue. UCB’s 2021 revenue was reduced by 4.57% vs. 2020. On Feb’21, UCB collaborated with Microsoft to accelerate drug discovery & development under its immunology & neurology segments.

Immunology Segment Revenue: $2.13B

Founded Year: 2002

Market Cap: $16.40B

Total Employees: ~2,090

Headquarters: Delaware, United States

Stock Exchange: NASDAQ

Incyte is a biopharmaceutical company focused on the discovery, development & commercialization of proprietary therapeutics across therapeutic areas including Hematology, Oncology, Inflammation & Autoimmunity. The company’s net revenue was generated through its immunotherapy Jakafi. Incyte’s 2021 revenue was boosted by 10.36% vs. 2020. On Sep’21 Incyte entered into a collaboration with Syndax for the development & commercialization of Axatilimab to treat cGvHD & other fibrotic diseases.

Immunology Segment Revenue: $3.31B

Founded Year: 1887

Market Cap: $160.06B

Total Employees: ~32,200

Headquarters: New York, United States

Stock Exchange: NYSE

Bristol-Myers Squibb (BMS) is a pharmaceutical company that focuses on oncology, cardiovascular & immunological diseases. The immunological segment of the company contains Orencia. BMS’s 2021 revenue was boosted by 4.75% vs. 2020. On Aug’21, BMS in-licensed Exscientia’s immune-modulating drug candidate for multiple therapeutic areas including immunology & oncology  

Immunology Segment Revenue: $3.36B

Founded Year: 1876

Market Cap: $287.92B

Total Employees: ~35,000

Headquarters: Indiana, United States

Stock Exchange: NYSE

Eli Lilly is a pharmaceutical company that focuses on the development, manufacturing & marketing of pharmaceutical products across immunology, neurodegenerative diseases & endocrinology. The company provides Taltz & Olumiant under its immunotherapies. Eli Lilly’s 2021 revenue showcased a hike of 36.58% vs. 2020. In Feb’21, Lilly and Rigel joined forces to develop RIPK1 Inhibitors for Immunological & Neurodegenerative Diseases.

Immunology Segment Revenue: $3.8B

Founded Year: 1781

Market Cap: $46.18B

Total Employees: ~47,000

Headquarters: Tokyo, Japan

Stock Exchange: NYSE

Takeda is a Japanese multinational biopharmaceutical company with its main target area including Metabolic Disorders, Gastroenterology, Neurology, Inflammation, Immunology & Oncology. The company’s approved immunotherapies include Immunoglobulin & Albumin. Takeda’s 2021 revenue escalated by 6.74% vs. 2020. On Sep’21, MHLW (Japan) granted Takeda’s Alofisel a manufacturing & marketing approval in Japan to treat Non-active or Mildly Active Luminal Crohn’s Disease.

Immunology Segment Revenue: $4.43B

Founded Year: 1849

Market Cap: $2.40B

Total Employees: ~79,000

Headquarters: New York, United States

Stock Exchange: NYSE

Pfizer is a global pharmaceutical company that discovers, develops, manufactures & distributes biopharmaceutical products for immunology, oncology, cardiology, endocrinology & neurology. Among the company’s immunotherapies, Xeljanz has generated $2.45B in revenue from the overall revenue. Pfizer’s 2021 revenue declined by 3% vs. 2020. On Jan’21, Pfizer made a $25M investment in Vedanta as a part of its Breakthrough Growth Initiative.

Immunology Segment Revenue: $5.78B

Founded Year: 1996

Market Cap: $210.35B

Total Employees: ~108,000

Headquarters: Basel, Switzerland

Stock Exchange: SWX

Novartis is a multinational pharmaceutical company that targets therapeutic areas including Immunology, Dermatology, Cardio-Metabolic, Oncology, Neurology & Ophthalmology. The company’s immunology segment includes Cosentyx & Ilaris along with other immunotherapies. Novartis’ 2021 revenue was raised by 18.90% vs. 2020. On Oct’21, Novartis entered into a strategic partnership with Innodem Neurosciences to conduct a breakthrough clinical trials.

Immunology Segment Revenue: $6.3B

Founded Year: 1973

Market Cap: $1.86B

Total Employees: ~95,440

Headquarters: Paris, France

Stock Exchange: NASDAQ

Sanofi is a global healthcare provider of solutions across various countries focused on the therapeutic area including, CVD, Neurology, Diabetes, Internal Medicine, Oncology, Thrombosis & Vaccines. The company’s immunotherapies Dupixent ($5.25B) & Kevzara ($0.29B) have contributed to its immunology revenue. Sanofi’s 2021 revenue increased by 36.96% vs. 2020. In Apr’21, Sanofi acquires Tidal Therapeutics to utilize Tidal’s mRNA-based research platform to expand its immunology & oncology segments.

Immunology Segment Revenue: $6.71B

Founded Year: 1980

Market Cap: $132.67B

Total Employees: ~24,200

Headquarters: California, United States

Stock Exchange: NASDAQ

Amgen is a biotechnology company that provides treatment options for diseases including, CVD, oncology, bone health, neuroscience, immunology, nephrology & inflammation. The total sale obtained by the company included the sales Enbrel & Otezla. Amgen’s 2021 revenue decreased by 6.67% vs. 2020. On Jun’21, Amgen and Kyowa Kirin collaborated to jointly develop and commercialize KHK4083 to treat Atopic Dermatitis.

Immunology Segment Revenue: $8.89B

Founded Year: 1896

Market Cap: $278.79B

Total Employees: ~100,920

Headquarters: Basel, Switzerland

Stock Exchange: SWX

Roche is a Swiss-based multinational healthcare company that functions under two divisions, Pharmaceutical & Diagnostics. The company’s immunology section delivers products for rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis & giant cell arteritis. Its immunotherapy Actemra contributed a sale of $3.78B to the overall sale. Roche’s 2021 revenue increased by 3.98% vs. 2020. On Jun’21 Roche entered into a research collaboration with Synlogic to develop novel therapies for inflammatory bowel diseases.

Immunology Segment Revenue: $16.75B

Founded Year: 1886

Market Cap: $447.43B

Total Employees: ~141,700

Headquarters: New Jersey, United States

Stock Exchange: NYSE

Johnson & Johnson (J&J) is an American multinational healthcare company that delivers products in therapeutic areas including Neuroscience, Oncology, Immunology, Cardiovascular, Metabolism & Pulmonary Hypertension. Under its Immunological segment, the company focuses on diseases including rheumatoid arthritis, inflammatory bowel diseases & psoriasis. J&J’s 2021 revenue increased by 11.29% vs. 2020. Stelara generated $9.13B in revenue from the overall sale in its immunology segment. In Apr’21, J&J submitted an MAA to EMA for the approval of BCMA CAR-T therapy cilta-cel to treat multiple myeloma.

Immunology Segment Revenue: $25.24B

Founded Year: 2013

Market Cap: $247.84B

Total Employees: ~50,000

Headquarters: New York, United States

Stock Exchange: NYSE

Abbvie is a biopharmaceutical company focused on the development of products across key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics & eye care. The company’s immunological segment includes Humira, Skyrizi & Rinvoq from which Humira individually generated revenue of $20.69B out of Abbvie’s total sales. AbbVie's 2021 revenue increased by 14.13% vs. 2020. On Jan’21, Abbvie’s Rinvoq received the EU approval for the treatment of Psoriatic Arthritis and Ankylosing Spondylitis.

Sources:

• Annual reports
• SEC filings
• Press releases
• Company websites

Market Cap Source: Google finance (10^th August, 2022)

Currency Conversion: X-Rates (10^th August, 2022)

Note:

• All revenues are reported in $B
• The revenue for Astellas increased in JPY by 1.48% but decreased in USD due to the currency rate drop
• The revenue for UCB increased in EUR by 2.56% but decreased in USD due to the currency rate drop

Related Post: Top 20 Immunology Companies Based on 2020 Immunology Segment Revenue